PA
IONS icon

PharVision Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

PharVision Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,661
Closed -$211K – 370
2025
Q4 		$211K Sell
2,661
-926
-26% -$69.7K 0.11% 515
2025
Q3 		$235K Buy
+3,587
New +$175K 0.13% 378

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's IONS Position: Q1 2026 in Review

PharVision Advisers sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 2,661 shares — an estimated $211K sold.

PharVision Advisers first reported a position in IONS in Q3 2025 and held it in 2 quarters. The position peaked at $235K in Q3 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • PharVision Advisers reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 2,661 Ionis Pharmaceuticals shares in Q1 2026, an estimated $211K.
  • PharVision Advisers first reported a position in Ionis Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Ionis Pharmaceuticals position peaked at $235K in Q3 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.